Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL1 tumor cells refer to a transplantable murine B-cell leukemia cell line (BCL1, RRID:CVCL_0166) established from a spontaneous lymphoma in a female BALB/c mouse, serving as a model for human prolymphocytic leukemia (PLL). In syngeneic mice, injection leads to massively enlarged spleens followed by leukemia, with strong dependence on host lymphoid tissue microenvironment; splenectomy alters growth kinetics, delaying leukemia onset and shifting infiltration to lymph nodes. Note: "BCL1" is sometimes confused with the CCND1 gene (cyclin D1, alias BCL1), a cell cycle regulator and therapeutic target in mantle cell lymphoma via t(11;14) translocation, but the query specifies "BCL1 tumor cells," identifying the cell line, not the gene/protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL1 tumor cells (BCL1).